Biogen Acquires RayThera for Up to $1 Billion
Biogen has agreed to acquire RayThera Inc., a private biotechnology company focused on small-molecule anti-inflammatory therapies, in a deal worth up to $1 billion. The transaction includes an upfront payment and potential milestone-based payments tied to clinical and regulatory achievements.
Tickers: $BIIB
Topics: acquisition biotechnology drug development immunology